Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Charcot-Marie-Tooth disease (CMT) is one of the most common inherited neurological disorders. More than 40 genes have been identified in CMT, and each gene is associated with one or more diseases. In addition, several genes can be associated with one type of CMT. More than half of CMT cases are caused due to duplication of the PMP22 gene on chromosome 17. There are different types of CMT diseases, such as CMT1 (caused by myelin sheath abnormalities), CMT2 (peripheral nerve cell axon abnormalities), and CMT3 or dejerine-sottas disease is a particularly serious demyelinating neuropathy, that begins in infancy.

The global charcot-marie-tooth disease market is estimated to be valued at US$ 793.9 Million in 2021 and is expected to increase to US$ 3,459.1 Million by 2028, witnessing a CAGR of 23.4% over the forecast period (2021-2028).

Figure 1. Global Charcot-Marie-Tooth Disease Market Value (US$ Mn) & Y-o-Y Growth (%)

Charcot-Marie-Tooth Disease  | Coherent Market Insights

Increasing prevalence of charcot-marie-tooth disease is expected to drive the growth of the global charcot-marie-tooth disease market.

Increasing prevalence of charcot-marie-tooth disease is expected to drive the growth of the global charcot-marie-tooth disease market. For instance, according to the information provided by MedlinePlus in September 2020, charcot-marie-tooth disease is the most common genetic disease, involving peripheral nerves and affecting the population. One in every 3,300 people in the world is affected by the disease. Furthermore, according to the same source, 70% to 80% of CMT1 patients have mutations that affect the PMP22 gene. Most of these situations occur when there are extra copies of the gene due to a small duplication of genetic material on chromosome 17. Another 10% to 12% of CMT1 patients have mutations in the MPZ gene. The most common cause of CMT2 is a mutation in the MFN2 gene, which accounts for about 20% of cases of total CMT cases. Approximately 90% of CMTX patients have mutations in the GJB1 gene.

request-sample

Charcot-Marie-Tooth Disease Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 793.9 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 23.4% 2028 Value Projection: US$ 3,459.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Disease Type: CMT 1, CMT 2, CMT 3, Others
  • By Drug Type: Nonsteroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors, Tricyclic antidepressants, Anticonvulsants, Analgesics, Pipeline Drug
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc.

Growth Drivers:
  • Increasing incidence and prevalence of CMT
  • Development of Novel Therapeutics for the Treatment of CMT Disease
Restraints & Challenges:
  • Increased risk of tumor recurrence 
  • Difficulty of diagnosis due to high treatment costs

Figure 2. Global Charcot-Marie-Tooth Disease Market Share (%), By Region, 2021

Charcot-Marie-Tooth Disease  | Coherent Market Insights

Global Charcot-Marie-Tooth Disease Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sector, which is majorly impacted by the COVID-19 pandemic.

The COVID-19 pandemic caused major disruptions to clinical trial executions in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced disturbances, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, contract research organizations, and other organizations that support drug development shifted to remote working environments.

Global Charcot-Marie-Tooth Disease Market: Restraint

The increased risk of tumor recurrence and the difficulty of diagnosis due to high treatment costs have hindered the global charcot-marie-tooth disease market.

Key Players

Major players operating in the global charcot-marie-tooth disease market include Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc.

Charcot-marie-tooth (CMT) disease is caused by mutations in the genes that affect the structure and function of peripheral nerves that control movement and sensation. Defective genes can cause the nerve fibers (axons) or myelin sheaths (the fat layer that separates nerve fibers) to degenerate in the peripheral nerves. This weakens the transmission of nerve signals between the brain and limbs, causing muscle atrophy and decreased sensation. As charcot-marie-tooth disease progresses, symptoms will spread from the feet and legs to the hands and arms.

The severity of symptoms (that includes weakness in the legs, ankles, and feet, decreased muscle mass in the legs and feet, high foot arches, curled toes (hammer toes), and decreased walking and running ability, among others) varies from person to person, including between family members. The different types and subtypes of CMT are determined based on the mutant gene, genetic type, nerve conduction velocity, age of onset, disease severity, clinical symptoms, and peripheral nerve injury. The different types of CMT diseases include CMT1, CMT2, CMT3, CMT4, CMTX, and DICMT.

Market Dynamics

Increasing prevalence of charcot-marie tooth disease is one major factor driving the market growth. For instance, according to a data published by the Medscape in January 2021, the prevalence of CMT disease is one in 2,500 population, which is approximately 125,000 people in the U.S. The incidence of CMT 1 is 15 per 100,000 population; the incidence of CMT 1A is 10.5 per 100,000 population, or 70% of CMT 1. The incidence of CMT 2 is seven per 100,000 people. CMT X patients account for at least 10-20% of CMT syndrome patients.

Key features of the study:

  • This report provides in-depth analysis of the global charcot-marie-tooth disease market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global charcot-marie-tooth disease market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global charcot-marie-tooth disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global charcot-marie-tooth disease market

Detailed Segmentation:

  • Global Charcot-Marie-Tooth Disease Market, By Disease Type:
    • CMT 1
    • CMT 2
    • CMT 3
    • Others
  • Global Charcot-Marie-Tooth Disease Market, By Drug Type:
    • Nonsteroidal anti-inflammatory drugs
    • Cyclooxygenase-2 inhibitors
    • Tricyclic antidepressants
    • Anticonvulsants
    • Analgesics
    • Pipeline Drug
  • Global Charcot-Marie-Tooth Disease Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Charcot-Marie-Tooth Disease Market, By Region:      
    • North America
      • By Disease Type
        • CMT 1
        • CMT 2
        • CMT 3
        • Others
      • By Drug Type
        • Nonsteroidal anti-inflammatory drugs
        • Cyclooxygenase-2 inhibitors
        • Tricyclic antidepressants
        • Anticonvulsants
        • Analgesics
        • Pipeline Drug
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Disease Type
        • CMT 1
        • CMT 2
        • CMT 3
        • Others
      • By Drug Type
        • Nonsteroidal anti-inflammatory drugs
        • Cyclooxygenase-2 inhibitors
        • Tricyclic antidepressants
        • Anticonvulsants
        • Analgesics
        • Pipeline Drug
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Disease Type
        • CMT 1
        • CMT 2
        • CMT 3
        • Others
      • By Drug Type
        • Nonsteroidal anti-inflammatory drugs
        • Cyclooxygenase-2 inhibitors
        • Tricyclic antidepressants
        • Anticonvulsants
        • Analgesics
        • Pipeline Drug
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Disease Type
        • CMT 1
        • CMT 2
        • CMT 3
        • Others
      • By Drug Type
        • Nonsteroidal anti-inflammatory drugs
        • Cyclooxygenase-2 inhibitors
        • Tricyclic antidepressants
        • Anticonvulsants
        • Analgesics
        • Pipeline Drug
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Disease Type
        • CMT 1
        • CMT 2
        • CMT 3
        • Others
      • By Drug Type
        • Nonsteroidal anti-inflammatory drugs
        • Cyclooxygenase-2 inhibitors
        • Tricyclic antidepressants
        • Anticonvulsants
        • Analgesics
        • Pipeline Drug
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Disease Type
        • CMT 1
        • CMT 2
        • CMT 3
        • Others
      • By Drug Type
        • Nonsteroidal anti-inflammatory drugs
        • Cyclooxygenase-2 inhibitors
        • Tricyclic antidepressants
        • Anticonvulsants
        • Analgesics
        • Pipeline Drug
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Addex Therapeutics Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Affectis Pharmaceuticals AG
    • Genzyme Corp
    • Lead Discovery Center GmbH
    • Pharnext SA
    • Acceleron Pharma
    • MedDay Pharmaceuticals
    • Bristol-Myers-Squibb Company
    • Inflectis Bio Science Health Company
    • Helixmith Co., Ltd.
    • Neurogene Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Disease Type
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
      • Market Opportunity Map
  3. Global Charcot-Marie-Tooth Disease Market Insights
    • Drivers
    • Restraints
    • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Market Trends
    • Product Launches
    • Key Developments
    • Regulatory Scenario
    • Collaborations & Acquisitions
    • Epidemiology
    • PEST Analysis
  4. Global Charcot-Marie-Tooth Disease Market - Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact of COVID-19 on demand and supply chain
  5. Global Charcot-Marie-Tooth Disease Market, By Disease Type, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • CMT 1
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • CMT 2
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • CMT 3
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  6. Global Charcot-Marie-Tooth Disease Market, By Drug Type, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Nonsteroidal anti-inflammatory drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Cyclooxygenase-2 inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Tricyclic antidepressants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Anticonvulsants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Analgesics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Pipeline Drug
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  7. Global Charcot-Marie-Tooth Disease Market, By Distribution Channel, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  8. Global Charcot-Marie-Tooth Disease Market, By Region, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Region at Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Distribution Channel, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Distribution Channel, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Distribution Channel, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Distribution Channel, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Distribution Channel, 2017–2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country/Region, 2017–2028, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Snapshot
    • Company Profiles
      • Addex Therapeutics Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Affectis Pharmaceuticals AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Genzyme Corp
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Lead Discovery Center GmbH
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Pharnext SA
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Acceleron Pharma
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • MedDay Pharmaceuticals
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Bristol-Myers-Squibb Company
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Inflectis Bio Science Health Company
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Helixmith Co., Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Neurogene Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
  10. Section
    • Research Methodology
    • About us

*Browse 35 market data tables and 34 figures on "Charcot-Marie-Tooth Disease Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global charcot-marie-tooth market size is estimated to be valued at US$ 793.9 Million in 2021 and is expected to exhibit a CAGR of 23.4% between 2021 and 2028.
Increasing incidence and prevalence of CMT and development of novel therapeutics for the treatment of CMT disease are major driving factors for the market.
CMT 1 is the major disease type segment in the market.
The increased risk of tumor recurrence and the difficulty of diagnosis due to high treatment costs are the major factor restraining growth of the market.
Major players operating in the market include Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.